JP2016505621A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505621A5
JP2016505621A5 JP2015551794A JP2015551794A JP2016505621A5 JP 2016505621 A5 JP2016505621 A5 JP 2016505621A5 JP 2015551794 A JP2015551794 A JP 2015551794A JP 2015551794 A JP2015551794 A JP 2015551794A JP 2016505621 A5 JP2016505621 A5 JP 2016505621A5
Authority
JP
Japan
Prior art keywords
optionally substituted
item
alkyl
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015551794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505621A (ja
JP6450323B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/010247 external-priority patent/WO2014107622A1/en
Publication of JP2016505621A publication Critical patent/JP2016505621A/ja
Publication of JP2016505621A5 publication Critical patent/JP2016505621A5/ja
Application granted granted Critical
Publication of JP6450323B2 publication Critical patent/JP6450323B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015551794A 2013-01-07 2014-01-03 デオキシウリジントリホスファターゼ阻害剤 Active JP6450323B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361749791P 2013-01-07 2013-01-07
US61/749,791 2013-01-07
US201361874643P 2013-09-06 2013-09-06
US61/874,643 2013-09-06
PCT/US2014/010247 WO2014107622A1 (en) 2013-01-07 2014-01-03 Deoxyuridine triphosphatase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018206547A Division JP6660993B2 (ja) 2013-01-07 2018-11-01 デオキシウリジントリホスファターゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2016505621A JP2016505621A (ja) 2016-02-25
JP2016505621A5 true JP2016505621A5 (enExample) 2017-02-09
JP6450323B2 JP6450323B2 (ja) 2019-01-09

Family

ID=50030487

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015551794A Active JP6450323B2 (ja) 2013-01-07 2014-01-03 デオキシウリジントリホスファターゼ阻害剤
JP2018206547A Active JP6660993B2 (ja) 2013-01-07 2018-11-01 デオキシウリジントリホスファターゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018206547A Active JP6660993B2 (ja) 2013-01-07 2018-11-01 デオキシウリジントリホスファターゼ阻害剤

Country Status (7)

Country Link
US (3) US9809571B2 (enExample)
EP (1) EP2941423B1 (enExample)
JP (2) JP6450323B2 (enExample)
CN (1) CN105189478B (enExample)
CA (1) CA2914178C (enExample)
IL (1) IL239827B (enExample)
WO (1) WO2014107622A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105189478B (zh) * 2013-01-07 2019-10-22 南加州大学 脱氧尿苷三磷酸酶抑制剂
US9790214B2 (en) 2014-01-03 2017-10-17 University Of Southern California Heteroatom containing deoxyuridine triphosphatase inhibitors
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2017006283A1 (en) 2015-07-08 2017-01-12 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
JP6836589B2 (ja) * 2015-07-08 2021-03-03 シーブイ6 セラピューティクス (エヌアイ) リミテッド ヒダントインを含むデオキシウリジントリホスファターゼ阻害剤
EP3429996A4 (en) 2016-03-16 2020-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. SMALL MOLECULES AGAINST CEREBLON TO IMPROVE THE FUNCTION OF EFFECTOR T CELLS
CA3026149A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
WO2018098207A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10829457B2 (en) 2016-11-23 2020-11-10 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
US11168059B2 (en) 2016-11-23 2021-11-09 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US10858344B2 (en) 2016-11-23 2020-12-08 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11174271B2 (en) 2016-11-23 2021-11-16 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018128720A1 (en) 2017-01-05 2018-07-12 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
BR112019014814B1 (pt) 2017-01-23 2024-03-12 Novartis Ag Compostos, composições farmacêuticas dos mesmos e seus usos no tratamento de doenças associadas à disfunção de canais iônicos de potássio
SG11202012464WA (en) 2018-07-11 2021-01-28 H Lee Moffitt Cancer Center And Research Institute Inc Dimeric immuno-modulatory compounds against cereblon-based mechanisms
CA3116339A1 (en) 2018-10-22 2020-04-30 Cadent Therapeutics, Inc. Crystalline forms of potassium channel modulators
EP4171549A1 (en) 2020-06-26 2023-05-03 CV6 Therapeutics (NI) Limited Combination therapy with deoxyuridine triphosphatase inhibitors
WO2022197978A1 (en) * 2021-03-17 2022-09-22 President And Fellows Of Harvard College Compositions and methods for modulating mitochondrial function and biogenesis

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4829785B1 (enExample) 1970-03-26 1973-09-13
BE787766A (fr) * 1971-08-21 1973-02-19 Merck Patent Gmbh Imides d'acide glutarique et leur procede de preparation
US4063019A (en) 1976-03-30 1977-12-13 E. R. Squibb & Sons, Inc. [[[(2,4-Dioxo-1-imidazolidinyl)amino]carbonyl]amino]-acetylcephalosporin derivatives
US4304715A (en) 1979-06-08 1981-12-08 Derek Hudson Enkephalin analogues
DE3027596A1 (de) 1980-07-21 1982-02-18 Bayer Ag, 5090 Leverkusen Triazolidin-3,5-dion-oxyalkylverbindungen und verfahren zu ihrer herstellung
JPS5839672A (ja) 1981-09-03 1983-03-08 Chugai Pharmaceut Co Ltd ウラシル誘導体
JPS60243017A (ja) 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
JPH0674251B2 (ja) 1986-02-07 1994-09-21 全薬工業株式▲会▼社 ビス−ジオキソピペラジン誘導体
JPS63101361A (ja) * 1986-09-08 1988-05-06 ブリティッシュ・テクノロジー・グループ・リミテッド ジオキソピペリジン誘導体を含有する不安解消組成物
FR2644786B1 (fr) 1989-03-21 1993-12-31 Adir Cie Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5599796A (en) 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
AU3935895A (en) 1994-11-24 1996-06-17 Takeda Chemical Industries Ltd. Alpha-ketoamide derivatives as cathepsin l inhibitor
WO1997036916A1 (en) 1996-03-29 1997-10-09 The University Of Medicine And Dentistry Of New Jersey dUTPASE, ITS ISOFORMS, AND DIAGNOSTIC AND OTHER USES
JPH09286786A (ja) 1996-04-18 1997-11-04 Nippon Paper Ind Co Ltd ピリミジン誘導体及びその抗腫瘍剤としての用途
DE19756212A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
JP4524039B2 (ja) 1997-12-18 2010-08-11 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Srcファミリーsh2ドメインインヒビターとしてのピリドン
CA2366264A1 (en) 1999-04-02 2000-10-12 Bristol-Myers Squibb Company Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase
DE10002509A1 (de) * 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
WO2002074750A1 (en) 2001-03-15 2002-09-26 Astrazeneca Ab Metalloproteinase inhibitors
JP2002284686A (ja) 2001-03-28 2002-10-03 Sankyo Co Ltd スルホンアミド化合物を含有する医薬組成物
WO2002083651A2 (en) 2001-04-11 2002-10-24 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
WO2004009559A2 (en) 2002-07-18 2004-01-29 Queen's University At Kingston Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
US7125865B2 (en) 2002-07-25 2006-10-24 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
GB0221246D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0400290D0 (en) 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
AR052196A1 (es) 2005-01-25 2007-03-07 Celgene Corp Metodos y composiciones que utilizan 4-amino-2-(3-metil-2,6- dioxopiperidin-3-il)-isoindol-1,3-diona
WO2006135763A2 (en) 2005-06-09 2006-12-21 The Johns Hopkins University Inhibitors of dna repair enzymes and methods of use thereof
UA95955C2 (ru) 2006-07-24 2011-09-26 Кореа Ресерч Инститьют Оф Кемикал Текнолоджи Ингибиторы обратной транскриптазы вич
EP1939186A1 (en) 2006-12-22 2008-07-02 Sulfidris S.r.l. 5-Fluorouracil derivatives and their use for the treatment of cancer
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
ES2392220T3 (es) 2008-06-03 2012-12-05 Taiho Pharmaceutical Co., Ltd. Compuesto de uracilo que tiene actividad inhibidora sobre la desoxiuridina trifosfatasa humana o una sal del mismo
WO2010025308A2 (en) 2008-08-27 2010-03-04 Universtiy Of Southern California Inhibitors of dutpase
JP2011231015A (ja) 2008-08-29 2011-11-17 Taiho Yakuhin Kogyo Kk 含窒素複素環を有する新規ウラシル化合物又はその塩
WO2010102886A1 (en) 2009-02-19 2010-09-16 Novo Nordisk A/S Modification of factor viii
CN102458393B (zh) 2009-06-25 2014-08-20 生物验证系统股份公司 治疗肺结核的组合物
JP2013032293A (ja) * 2009-11-30 2013-02-14 Taiho Yakuhin Kogyo Kk ヒトdUTPase阻害活性を有する5−フルオロウラシル化合物又はその塩
MY161094A (en) * 2009-11-30 2017-04-14 Taiho Pharmaceutical Co Ltd Anti-tumor effect potentiator
JP2013047189A (ja) 2009-12-25 2013-03-07 Kyorin Pharmaceutical Co Ltd 新規パラバン酸誘導体及びそれらを有効成分とする医薬
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
JP6162694B2 (ja) 2011-07-18 2017-07-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ベンズアミド類
AP2014007637A0 (en) 2011-11-15 2014-05-31 Takeda Pharmaceutical Dihydroxy aromatic heterocyclic compound
CN105189478B (zh) 2013-01-07 2019-10-22 南加州大学 脱氧尿苷三磷酸酶抑制剂
US9790214B2 (en) 2014-01-03 2017-10-17 University Of Southern California Heteroatom containing deoxyuridine triphosphatase inhibitors
WO2015142001A2 (ko) 2014-03-21 2015-09-24 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
CN107613983B (zh) 2015-04-30 2021-05-04 大鹏药品工业株式会社 抗肿瘤剂的副作用减轻剂
MY185785A (en) 2015-05-01 2021-06-08 Taiho Pharmaceutical Co Ltd Novel crystal of uracil compound
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
WO2017006283A1 (en) 2015-07-08 2017-01-12 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
JP6836589B2 (ja) 2015-07-08 2021-03-03 シーブイ6 セラピューティクス (エヌアイ) リミテッド ヒダントインを含むデオキシウリジントリホスファターゼ阻害剤
US11168059B2 (en) 2016-11-23 2021-11-09 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US11174271B2 (en) 2016-11-23 2021-11-16 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018098207A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10858344B2 (en) 2016-11-23 2020-12-08 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10829457B2 (en) 2016-11-23 2020-11-10 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018128720A1 (en) 2017-01-05 2018-07-12 Cv6 Therapeutics (Ni) Limited Uracil containing compounds

Similar Documents

Publication Publication Date Title
JP2016505621A5 (enExample)
JP2017502967A5 (enExample)
JP2019014758A5 (enExample)
CL2023001738A1 (es) Inhibidores de prmt5
RU2018103907A (ru) Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
JP2008535902A5 (enExample)
JP2020530496A5 (enExample)
RU2017145026A (ru) Соединение, ингибирующее brk
RS65214B1 (sr) Modulatori integrisanog puta stresa
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
CA2936551A1 (en) Substituted pyrrolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases
JP2019518741A5 (enExample)
TW201808914A (zh) 整合應激途徑之調節劑
KR20190022520A (ko) Hdac 억제제 및 pd-l1 억제제의 병용 요법
CN111386128A (zh) 用于免疫调节的联合疗法
JP2013530964A5 (enExample)
IL273727B2 (en) Lysyl oxidase inhibitors
RU2016146819A (ru) Композиции и способы модулирования экспрессии рецептора гормона роста
JP6871868B2 (ja) 免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤
CN110769837A (zh) 与五氮杂大环状环配合物的联合癌症免疫疗法
EA201171415A1 (ru) Ингибиторы белков семейства iap
RU2012125971A (ru) Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных
BR112020008537A2 (pt) inibidores duplos de vias da tim-3 e da pd-1
US20250339416A1 (en) Ezh1/2 dual inhibitor-containing pharmaceutical composition to be used as a combination drug
EA200800516A1 (ru) Производные n-фенил-2-пиримидинамина и процесс их получения